For a patient with an eGFR of 52 mL/min and bursitis, is there merit in prescribing cefalexin (Keflex) 500 mg orally four times daily for five days and then reassessing?

Cephalexin 500mg QID for 5 Days in Bursitis with Reduced eGFR

For a patient with bursitis and an eGFR of 52 mL/min, prescribing cephalexin 500 mg four times daily for 5 days with reassessment is appropriate, though dose adjustment may be warranted given the renal impairment.

Dosing Considerations with Renal Impairment

The standard adult dose of cephalexin is 250 mg every 6 hours, with 500 mg doses reserved for more severe infections or less susceptible organisms 1. Your proposed regimen of 500 mg QID (2000 mg/day total) falls within the FDA-approved range of 1-4 grams daily 1.

Renal Dose Adjustment Required

• With an eGFR of 52 mL/min (moderate renal impairment), dose adjustment is necessary because cephalexin is primarily renally cleared 2
• Pharmacokinetic studies demonstrate that serum half-life increases significantly with declining renal function, reaching 8.47 hours in anephric patients compared to 1.03 hours in normal subjects 2
• The elimination rate constant correlates directly with creatinine clearance (Ke = 0.0766 + 0.0060 × CrCl), meaning your patient will accumulate drug at standard dosing 2

Practical Dosing Recommendation

Consider reducing to 500 mg three times daily (TID) or 500 mg twice daily (BID) rather than QID for this patient:

• Studies demonstrate that cephalexin 500 mg BID is equally effective as QID dosing for skin and soft tissue infections, with >97% efficacy 3
• BID dosing showed equivalent clinical cure rates in multiple trials for dermatologic infections 4
• The lower frequency improves adherence without compromising effectiveness 5

Duration and Reassessment Strategy

Five-Day Duration is Evidence-Based

The IDSA guidelines specifically recommend 5 days as the standard duration for skin and soft tissue infections, with extension only if infection has not improved 6. This applies directly to your bursitis case.

• Treatment should be extended beyond 5 days only if clinical improvement is absent at reassessment 6
• The 5-day timepoint is the appropriate moment to evaluate response 6

Reassessment Parameters at Day 5

Look for these specific indicators:

• Reduction in erythema, warmth, and swelling over the bursa
• Decreased pain and improved range of motion
• Resolution of systemic signs (fever, if present initially)
• Ability to bear weight or use the affected joint without significant discomfort

Bursitis-Specific Considerations

Antibiotic Coverage

Cephalexin provides appropriate coverage for the most common pathogens in septic bursitis (Staphylococcus aureus and Streptococcus species) 6, 7:

• The IDSA guidelines list cephalexin 500 mg every 6 hours as an acceptable oral agent for non-purulent skin and soft tissue infections 6
• French guidelines for septic bursitis support oral cephalosporin use in outpatient management 7

Critical Caveat

If there is any concern for MRSA (history of MRSA colonization, injection drug use, or treatment failure), cephalexin is inadequate and alternative agents active against MRSA are required 6.

Optimal Regimen for This Patient

Prescribe cephalexin 500 mg orally three times daily (or twice daily) for 5 days, then reassess:

• The reduced frequency accounts for the eGFR of 52 mL/min 2
• BID or TID dosing maintains efficacy while improving safety and adherence 3, 4, 5
• The 5-day duration with mandatory reassessment follows IDSA guidelines 6
• Extend treatment only if clinical improvement is insufficient at day 5 6

Additional Management

• Ensure adequate drainage if fluctuance is present - antibiotics alone may be insufficient for undrained purulent collections 6
• Elevation and rest of the affected joint support antibiotic therapy 6
• Monitor for adverse effects, though cephalexin has a favorable safety profile even with mild-moderate renal impairment 1